Gene Panel Testing For Inherited Cancer Risk

And even qualify patients for clinical trials allowing you to.

Gene panel testing for inherited cancer risk.

2 recently gene panel tests or multigene. The risk of developing breast cancer is 65 for brca1 mutation carriers and patients with lynch syndrome have a 78 lifetime risk of developing colorectal cancer. Identify germline mutations that inform treatment or surgical intervention. By contrast dtc genetic testing for cancer risk often involves the analysis of common inherited genetic variants that individually are generally associated with only a minor increase in risk.

Even when added together all the known common variants associated with a particular cancer type account for only a small portion of a person s risk. Genetic testing for hereditary breast and ovarian cancer looks for mutations in the brca1 and brca2 genes your doctor might suggest testing using a multigene panel which looks for mutations in several genes at the same time including brca1 and brca2 if you are of ashkenazi jewish or eastern european ancestry your doctor might suggest testing for three specific brca1 and brca2 mutations. If a hereditary cancer risk assessment suggests an increased risk of a hereditary cancer syndrome referral to a specialist in cancer genetics or a health care provider with expertise in genetics is recommended for expanded gathering of family history information risk assessment education and counseling which may lead to genetic testing and. Thus gene panel testing is now an option in the setting of genetic counseling and testing for cancer risk.

Color analyzes genes including brca1 and brca2 associated with cancers where early knowledge can potentially make a difference. Genetic testing is recommended by professional guidelines for patients with breast ovarian endometrial colorectal pancreatic and prostate cancers. Testing can be performed in the context of assessing for mutations in the germline related to inherited cancer risk or testing for genetic mutations in a solid tumor or leukemia lymphoma to gain insights into somatic mutations involved in carcinogenesis and potentially inform targets for treatment. Results can reveal how quickly a cancer may progress.